Latest Prasugrel Stories

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine. The finding -- reported Nov. 4, 2012, at the American Heart Association's Scientific Sessions annual meeting and published in the Journal of the American Medical Association – provides new insights into a subset of heart patients with acute coronary syndromes...

Study finds that prasugrel may reduce cardiovascular events among patients managed medically after an angiogram for acute coronary syndrome A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy. Results of the TRILOGY ACS trial, Angiographic Cohort were presented today at the 24th annual Transcatheter...

MIAMI, Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness studies of U.S. hospital data comparing rates of readmission for subsequent heart attack and initial hospitalization costs among patients with acute coronary syndromes (ACS) treated with a percutaneous coronary intervention (PCI) and antiplatelet therapy, including Effient(®) (prasugrel) or...

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's...

Prasugrel versus clopidogrel for ACS patients managed without revascularization The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularization has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke. The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary...

Potential long-term benefit observed for first time in ACS patients The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists. The study also showed no difference in serious bleeding complications. At...

INDIANAPOLIS and TOKYO, Aug. 26, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an artery-opening procedure. At 30 months, 13.9 percent of prasugrel patients vs. 16.0 percent of...

Researchers report no significant difference in high versus low dose aspirin in preventing recurring cardiovascular events. Each year, more than one million Americans suffer a heart attack and nearly all patients are prescribed a daily aspirin and an antiplatelet medication during recovery.  However, the optimal aspirin dose has been unclear.  Now, new research from Brigham and Women's Hospital (BWH) reports that there is no significant difference between high versus low dose aspirin in...

New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome. Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall in patients with acute coronary syndromes (ACS), which are characterized by symptoms related to obstruction in coronary arteries, which supply blood to the...